FindTrial
Sign In

Efficacy and Safety of Remote Ischemic Conditioning in Improving Outcomes for Patients with Aortic Dissection Combined with Isolated Left Vertebral Artery: A Multi-Center, Open-Label, Randomized Controlled Clinical Trial

Efficacy and Safety of Remote Ischemic Conditioning in Improving Outcomes for Patients with Aortic Dissection Combined with Isolated Left Vertebral Artery: A Multi-Center, Open-Label, Randomized Controlled Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114585
Enrollment
Unknown
Registered
2025-12-15
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Dissection(Stanford Type A )

Interventions

Experimental group:RIC Joint Guidelines Recommended Treatment
Control group:Recommended treatment by the pseudo-intervention combined guidelines

Sponsors

The First Affiliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Aged 18-60 years; 2.CTA-confirmed Stanford Type A aortic dissection with isolated left vertebral artery (ILVA), undergoing aortic arch replacement concomitant with ILVA-left subclavian artery reconstruction; 3.Preoperative cranial CTA showing no cerebrovascular malformations, stenosis, hemorrhage, infarction, or related cerebrovascular diseases; 4.Participants or legally authorized representatives provide written informed consent for clinical trial participation and interventions.

Exclusion criteria

Exclusion criteria: 1.Contraindications to remote ischemic conditioning: severe upper limb soft tissue injury, fractures, Raynaud's syndrome, or peripheral vascular diseases; 2.History of truncal vagotomy or vagal nerve blockade; 3.Stenosis or severe malformation of subclavian, carotid, or femoral arteries/veins; 4.Concurrent additional surgical procedures; 5.Severe cardiac dysfunction, acute coronary syndrome, malignant hypertension, or cardiogenic shock; 6.Severe cerebral/pulmonary/hepatic/renal impairment, clinically significant coagulopathy, malignancy, autoimmune disorders, severe anemia, or major psychiatric conditions; 7.Pregnancy or lactation; 8.Participant or legal representative declines informed consent.

Design outcomes

Primary

MeasureTime frame
Modified Rankin Scale (mRS) score of 0-2 at 90 days postoperatively;—

Secondary

MeasureTime frame
The mRS score was 0 to 1 at 90 days postoperatively;MACCE at 90 days post-surgery;Incidence of complications related to left vertebral-basilar artery stenosis or occlusion;Postoperative ICU length of stay;—

Countries

China

Contacts

Public ContactShi Tao

The First Affiliated Hospital of Xi'an Jiaotong University

shi2009tao@163.com+86 29 8532 3865

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026